Lymphoma clinical trials in Ohio
28 studies for Lymphoma are looking for participants at sites in Ohio.
Cities in Ohio
Epco, Zanu, Ritux for R/R FL or MZL
- The Ohio State University Wexner Medical Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06563596Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 1
24 Months – 18 Years · All sexes · Updated Sep 25, 2026 · NCT06441331A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07015242Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT04301076A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Cincinnati, Cincinnati
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07221500Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Cleveland
RecruitingPhase 3
Ages 18 to 18 · All sexes · Updated Sep 8, 2026 · NCT07509151A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 2
1 Month – 17 Years · All sexes · Updated Sep 1, 2026 · NCT04570423Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
- Cleveland Clinic, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT07192471A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
- Cleveland Clinic, Cleveland
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Aug 20, 2026 · NCT06678659A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- University of Cincinnatti Medical Center, Cincinnatti
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06528301Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
- Cleveland Clinical Taussig Cancer Center, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- The Ohio State University Wexner Medical Center James Cancer, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT07465835A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05475925Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Jun 4, 2026 · NCT06131801Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
- The Ohio State University, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 24, 2026 · NCT06801002CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Cleveland Clinic, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT07356245The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Cleveland Clinic, Cleveland
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2025 · NCT06916767HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Aug 28, 2025 · NCT07145411From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.